These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 18389873)

  • 1. [Methodology of pharmacoeconomic studies in oncology].
    Ballatori E
    Recenti Prog Med; 2008 Jan; 99(1):42-7. PubMed ID: 18389873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic and quality of life outcomes: the four-step pharmacoeconomic research model.
    Arikian SR; Suver J; Einarson T; Doyle J
    Oncology (Williston Park); 1995 Nov; 9(11 Suppl):33-6. PubMed ID: 8608054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
    Weintraub WS
    J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):107-19. PubMed ID: 18495905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Economic evaluation in oncology].
    Schöffski O
    Med Klin (Munich); 2000 Jun; 95 Suppl 1():14-7. PubMed ID: 10941248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining types of economic evaluation.
    Ngorsuraches S
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S21-7. PubMed ID: 19255985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy.
    Navarro RP; Morrow T; Baran R
    Manag Care Interface; 2002 Jul; 15(7):55-62. PubMed ID: 12143298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical review of the full economic evaluations of pharmacological treatments for colorectal cancer.
    Garattini L; Compadri PD; Koleva D; Pasina L; Nobili A
    J Med Econ; 2008; 11(1):177-97. PubMed ID: 19450119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars.
    Henry D; Taylor C
    Semin Oncol; 2014 Apr; 41 Suppl 3():S13-20. PubMed ID: 24767632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.
    Yong JH; Beca J; Hoch JS
    Pharmacoeconomics; 2013 Mar; 31(3):229-36. PubMed ID: 23322588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacoeconomics of acne treatment: where are we heading?
    Inglese MJ; Fleischer AB; Feldman SR; Balkrishnan R
    J Dermatolog Treat; 2008; 19(1):27-37. PubMed ID: 18273722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Economic effects of "molecular" medicine].
    Riemann JF
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1740. PubMed ID: 17713881
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacoeconomics and cost of cancer drugs].
    Camps Herrero C; Caballero Díaz C; Blasco Cordellat A
    Farm Hosp; 2010 Mar; 34 Suppl 1():12-5. PubMed ID: 20920852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of modeling to evaluate the cost-effectiveness of cancer screening programs.
    Knudsen AB; McMahon PM; Gazelle GS
    J Clin Oncol; 2007 Jan; 25(2):203-8. PubMed ID: 17210941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Methods for analyzing uncertainty].
    Ferriols R; Alós M
    Farm Hosp; 2011 May; 35 Suppl 2():3-9. PubMed ID: 22445503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost-effectiveness analysis of 5-HT3 receptor antagonist drugs in cancer chemotherapy].
    Ishimaru H; Takayama S; Shiokawa M; Inoue T
    Gan To Kagaku Ryoho; 2008 Apr; 35(4):619-23. PubMed ID: 18408430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology.
    Knox KS; Adams JR; Djulbegovic B; Stinson TJ; Tomor C; Bennet CL
    Ann Oncol; 2000 Dec; 11(12):1591-5. PubMed ID: 11205468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacoeconomics in contemporary medicine].
    Czech M
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():16-9. PubMed ID: 15524007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost of medications in the oncology sector in the context of health economics].
    Walter E; Batista A
    Wien Med Wochenschr; 2008; 158(7-8):227-33. PubMed ID: 18500477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inequalities in oncology care: Economic consequences of high cost drugs.
    Niezen MG; Stolk EA; Steenhoek A; Uyl-De Groot CA
    Eur J Cancer; 2006 Nov; 42(17):2887-92. PubMed ID: 16979891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacoeconomics. I].
    Kolár J
    Ceska Slov Farm; 1997 Feb; 46(1):9-13. PubMed ID: 9221090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.